best-in-class therapeutic index

Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload

Amsterdam, Netherlands:  In vivo efficacy on a par with gold standard deruxtecan-based ADCs Poster to be presented at World ADC…

Read More »